## OMCL: Omnicell, Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_20 at 14.1% exceeds exhaustion threshold (10.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($39.99)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_20 drops below exhaustion threshold

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Announcing Omnicell Titan XT, the Next Generation, Automated Dispensing System Designed to Empower Autonomous Medication Management**
- Source: Yahoo Finance | 20251208T130915 | Bullish | Relevance: 98%
-  Omnicell, Inc. has launched Omnicell Titan XT, an automated dispensing system designed to transform medication management in healthcare. This system unifies automation and AI-enabled intelligence through the OmniSphere platform, aiming to provide greater pharmacy control and nursing confidence. It introduces features like DynamicRestock for pharmacy tasks and FiveRights safeguards for nurses, with future plans to integrate more care areas.

**2. 1 Healthcare Stock with Impressive Fundamentals and 2 We Brush Off**
- Source: Markets Financial Content | 20251208T040915 | Neutral | Relevance: 98%
-  This article evaluates three healthcare stocks, recommending McKesson (MCK) due to its strong financials, market scale, and effective share repurchases. Conversely, Omnicell (OMCL) and Labcorp (LH) are identified as less attractive investments due to stagnant sales, declining margins, and increased costs. The analysis provides fundamental reasons for investors to consider buying McKesson while being cautious about Omnicell and Labcorp.

**3. Reassessing Omnicell (OMCL) Valuation After Recent Share Price Momentum**
- Source: Simply Wall Street | 20251207T073223 | Bullish | Relevance: 98%
-  Omnicell (OMCL) has seen recent positive share price momentum, up 11% in the past week and 25% in three months, despite a weak year overall. The article suggests this performance reflects a cautious re-rating of the stock, which is considered potentially undervalued with a narrative fair value near $47.33, driven by its OmniSphere platform adoption. However, a traditional valuation approach shows the stock as stretched at 91 times earnings, highlighting a potential thin margin of safety.

**4. Omnicell launches Titan XT automated dispensing system for hospitals By Investing.com**
- Source: Investing.com India | 20251208T132415 | Bullish | Relevance: 98%
- Omnicell (NASDAQ:OMCL) has launched Titan XT, an enterprise automated dispensing system designed to improve medication management in healthcare. This system operates on Omnicell’s HITRUST-certified cloud platform, OmniSphere, aiming to enhance inventory control for pharmacies and administration confidence for nurses. The launch comes amidst strong financial performance for Omnicell, with its stock up over 12% recently and the company earning a perfect Piotroski Score of 9, signaling excellent operational efficiency.

**5. Announcing Omnicell Titan XT, the Next Generation, Automated Dispensing System Designed to Empower Autonomous Medication Management**
- Source: Markets Financial Content | 20251208T080000 | Bullish | Relevance: 97%
-  Omnicell, Inc. has launched Omnicell Titan XT, an enterprise automated dispensing system powered by OmniSphere, aimed at autonomous medication management. This system enhances medication management for growing health systems by providing greater pharmacy control and nursing confidence. Titan XT offers features like dynamic restock, centralized inventory control, AI-enabled intelligence for pharmacies, and safeguards like FiveRights for nurses to improve efficiency and patient safety.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Benchmark | $50 | $45 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Benchmark | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 8 ($1.29M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 58.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Blackrock Inc.: 17.1% (-2.3%)
- Vanguard Group Inc: 12.5% (-0.4%)
- Dimensional Fund Adv: 5.3% (+9.1%)
- Cadian Capital Manag: 4.7% (+25.9%)
- State Street Corpora: 4.6% (-2.0%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +4.2% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.28 elevated, pricing in significant growth expectations. Forward P/E 23.7x stretched relative to 8% growth. Analyst sentiment positive (1 raises, avg +11%). Insider selling cluster ($1.3M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.0B |
| Beta | 0.83 |
| 52W Range | $22.66 - $47.70 |
| Short Interest | 7.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.28 |
| Forward P/E | 23.7 |
| Current P/E | 25.4 |
| YoY Growth | 7.5% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from 9.8% to 14.1% (+4.2% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (14.1% > 10.0%), caution on chasing. MRS_5 at 4.5% confirms short-term momentum alignment. AM_20 at 16.5% shows strong absolute momentum above own 20MA. Outperforming sector by 18.6pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.63), confirming momentum. RSI overbought at 78, risk of mean reversion. Elevated volume (2.1x 20MA), institutional activity likely.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 14.09% (CS: 98) | Strong |
| RSI_14 | 77.8 | Overbought |
| MACD Histogram | 0.63 | Bullish |
| vs SMA20 | 1.165x | Above |
| vs SMA50 | 1.284x | Above |
| vs SMA200 | 1.364x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $43.49
- **Stop Loss:** $39.99 (8.0% risk)
- **Target:** $46.99 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 85
- **Position Value:** $3,696.65
- **Portfolio %:** 3.70%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-05 (Est: $0.49)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.36 | $0.51 | +40.7% |
| 2025Q2 | $0.27 | $0.45 | +66.7% |
| 2025Q1 | $0.20 | $0.26 | +27.1% |
| 2024Q4 | $0.58 | $0.60 | +2.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*